All Stories

  1. Noninvasive evaluation of pulmonary artery pressure during exercise: the importance of right atrial hypertension
  2. The haemodynamic basis of lung congestion during exercise in heart failure with preserved ejection fraction
  3. The neurohormonal basis of pulmonary hypertension in heart failure with preserved ejection fraction
  4. Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction
  5. Is it time to recognize a new phenotype? Heart failure with preserved ejection fraction with pulmonary vascular disease
  6. Long-term cardiovascular changes following creation of arteriovenous fistula in patients with end stage renal disease
  7. Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction
  8. Defining HFpEF: where do we draw the line?
  9. Taking aim at pulmonary hypertension in heart failure with preserved ejection fraction
  10. The Hemodynamic Basis of Exercise Intolerance in Tricuspid Regurgitation
  11. MY APPROACH to heart failure with preserved ejection fraction
  12. Impact of chronic changes in arterial compliance and resistance on left ventricular ageing in humans
  13. Impact of General and Central Adiposity on Ventricular-Arterial Aging in Women and Men
  14. Exercise haemodynamics and outcome in patients with dyspnoea
  15. Differential Hemodynamic Effects of Exercise and Acute Volume Expansion in HFpEF
  16. Hemodynamic Basis for Exercise Intolerance in Right Heart Failure Due to Tricuspid Regurgitation
  17. Differential Response to Low Dose Dopamine or Nesiritide in Patients with Acute Heart Failure and Renal Dysfunction in Accordance to LV EF: Sub-Group Analysis of the ROSE AHF Trial
  18. Invasive Hemodynamic Characterization of Heart Failure with Preserved Ejection Fraction
  19. Implications of Coronary Artery Disease in Heart Failure With Preserved Ejection Fraction
  20. Effects of Healthy Aging on the Cardiopulmonary Hemodynamic Response to Exercise
  21. Response to Letters Regarding Article, “Systemic Hypertension in Low-Gradient Severe Aortic Stenosis With Preserved Ejection Fraction”
  22. Resting Ventricular–Vascular Function and Exercise Capacity in Heart Failure With Preserved Ejection Fraction
  23. Right heart dysfunction in heart failure with preserved ejection fraction
  24. The pathophysiology of heart failure with preserved ejection fraction
  25. The sHunt for better breathing in heart failure with preserved ejection fraction
  26. Heart Failure with Preserved Ejection Fraction: Current Understandings and Challenges
  27. Fatness, Fitness, Stiffness, and Age
  28. Use of Metformin in Diseases of Aging
  29. Adverse Effects of Interstitial Pulmonary Edema on Pulmonary Hemodynamics and Right Heart Function in Heart Failure
  30. GALECTIN-3 IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: A RELAX SUBSTUDY
  31. EFFECT OF VASODILATOR THERAPY ON VALVULOARTERIAL IMPEDANCE AND DIASTOLIC FUNCTION IN LOW FLOW, LOW GRADIENT AORTIC STENOSIS WITH PRESERVED EJECTION FRACTION
  32. MEASURES OF PULSATILE ARTERIAL LOAD ARE ASSOCIATED WITH MYOCARDIAL WALL STRESS DURING SYSTOLE
  33. DIVERGING EFFECTS OF SILDENAFIL ON VENTRICULAR-VASCULAR FUNCTION IN HFPEF
  34. A Randomized Pilot Study of Aortic Waveform Guided Therapy in Chronic Heart Failure
  35. Interatrial pressure gradients during simulated obstructive sleep apnea: A catheter‐based study
  36. Effects of an Interatrial Shunt on Rest and Exercise Hemodynamics: Results of a Computer Simulation in Heart Failure
  37. Strain Improves Risk Prediction Beyond Ejection Fraction in Chronic Systolic Heart Failure
  38. Mechanisms of Exercise Intolerance in Heart Failure With Preserved Ejection Fraction
  39. Invasive Assessment of Pulmonary Hypertension
  40. Impact of Atrial Fibrillation on Exercise Capacity in Heart Failure With Preserved Ejection Fraction
  41. The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction
  42. Heart Rate Reduction
  43. Acute effects of atrial fibrillation on atrial and ventricular function: A simultaneous invasive-echocardiographic hemodynamic study
  44. Relationships Between Right Ventricular Function, Body Composition, and Prognosis in Advanced Heart Failure
  45. Systemic Hypertension in Low-Gradient Severe Aortic Stenosis With Preserved Ejection Fraction
  46. Ventricular-Arterial Coupling, Remodeling, and Prognosis in Chronic Heart Failure
  47. Longitudinal Changes in Left Ventricular Stiffness
  48. Clinical Features, Hemodynamics, and Outcomes of Pulmonary Hypertension Due to Chronic Heart Failure With Reduced Ejection Fraction
  49. Sildenafil and Exercise Capacity in Heart Failure—In Reply
  50. Invasive Measures of Afterload in Low Gradient Severe Aortic Stenosis With Preserved Ejection Fraction
  51. Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction
  52. Resting Heart Rate and Heart Rate Reserve in Advanced Heart Failure Have Distinct Pathophysiologic Correlates and Prognostic Impact
  53. Left Ventricular Dysfunction With Pulmonary Hypertension
  54. Aldosterone antagonism for HFpEF
  55. Hemodynamic Assessment in Patients on Chronic Continuous Flow Left Ventricular Assist Device Support
  56. Heart failure with preserved and reduced ejection fraction: different risk profiles for different diseases
  57. Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction
  58. Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction in Patients With Preserved Ejection Fraction
  59. Digging Deeper into Dyspnea
  60. Left Ventricular Dysfunction With Pulmonary Hypertension
  61. ACUTE HEMODYNAMIC EFFECTS OF SODIUM NITROPRUSSIDE IN LOW GRADIENT SEVERE AORTIC STENOSIS WITH PRESERVED EJECTION FRACTION
  62. RESTING VENTRICULAR-VASCULAR FUNCTION AND EXERCISE CAPACITY IN DIASTOLIC HEART FAILURE (DHF): A RELAX TRIAL ANCILLARY STUDY
  63. LONGITUDINAL CHANGES IN LEFT VENTRICULAR STIFFNESS: A COMMUNITY-BASED STUDY
  64. IMPACT OF ATRIAL FIBRILLATION ON EXERCISE CAPACITY IN DIASTOLIC HEART FAILURE: A RELAX TRIAL ANCILLARY STUDY
  65. Errata
  66. The Effect of Ageing on the Pulmonary Vasculature and Exercise Physiology
  67. Sex Differences in Arterial Stiffness and Ventricular-Arterial Interactions
  68. Hemodynamic Responses to Rapid Saline Loading
  69. Heart Failure With Preserved Ejection Fractiona
  70. Comorbidity and Ventricular and Vascular Structure and Function in Heart Failure With Preserved Ejection Fraction
  71. Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction
  72. TCT-829 Invasive Systemic Arterial Hemodynamics in Low Gradient Severe Aortic Stenosis with Preserved Ejection Fraction
  73. Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiency
  74. World Health Organization Pulmonary Hypertension Group 2: Pulmonary hypertension due to left heart disease in the adult—a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation
  75. PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) Trial
  76. Pulmonary Hypertension Due to Left Heart Disease
  77. The Reply
  78. Changes in Transmural Filling Pressure With Exercise in Patients With Diastolic Dysfunction and Preserved Systolic Function after Myocardial Infarction
  79. Electrophysiological and Hemodynamic Characteristics Associated With Obesity in Patients With Atrial Fibrillation
  80. Exercise Hemodynamics in Patients With and Without Diastolic Dysfunction and Preserved Ejection Fraction After Myocardial Infarction
  81. RIGHT TO LEFT SHUNTING THROUGH PATENT FORAMEN OVALE DURING SIMULATED EPISODES OF OBSTRUCTIVE SLEEP APNEA
  82. Letter by Forfia and Borlaug Regarding Article, “Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Target of Phosphodiesterase-5 Inhibition in a 1-Year Study”
  83. Pulmonary Capillary Wedge Pressure Augments Right Ventricular Pulsatile Loading
  84. Relationship Between Diastolic Function and Heart Rate Recovery After Symptom-Limited Exercise
  85. Effects of Vasodilation in Heart Failure With Preserved or Reduced Ejection Fraction
  86. Why are women more likely than men to develop heart failure with preserved ejection fraction?
  87. Bedside Assessment of Cardiac Hemodynamics: The Impact of Noninvasive Testing and Examiner Experience
  88. Ventricular–Vascular Interaction in Heart Failure
  89. A Novel Method Using the Valsalvagram in the Diagnosis of Heart Failure
  90. Diastolic and Systolic Heart Failure Are Distinct Phenotypes Within the Heart Failure Spectrum
  91. Discerning Pulmonary Venous From Pulmonary Arterial Hypertension Without the Help of a Catheter
  92. Invasive Hemodynamic Assessment in Heart Failure
  93. Diastolic relaxation and compliance reserve during dynamic exercise in heart failure with preserved ejection fraction
  94. HEMODYNAMIC RESPONSES TO ARTERIAL VASODILATION FUNDAMENTALLY DIFFER IN HEART FAILURE WITH PRESERVED VERSUS REDUCED EJECTION FRACTION
  95. Reply
  96. “Carcinoid‐Like” Tricuspid Valvulopathy Associated with Nephrogenic Systemic Fibrosis
  97. Sex, Load, and Relaxation
  98. Research Techniques
  99. Contributors
  100. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment
  101. Glycyrrhetinic acid attenuates vascular smooth muscle vasodilatory function in healthy humans
  102. Exercise Hemodynamics Enhance Diagnosis of Early Heart Failure With Preserved Ejection Fraction
  103. Global Cardiovascular Reserve Dysfunction in Heart Failure With Preserved Ejection Fraction
  104. The effect of loading alterations on left ventricular torsion: a simultaneous catheterization and two-dimensional speckle tracking echocardiographic study
  105. Size, Shape, and Stamina
  106. Heart Failure with Preserved Ejection Fraction: Pathophysiology and Emerging Therapies
  107. IS MID ASCENDING AORTIC DIAMETER SMALLER IN PATIENTS WITH HYPERTENSION OR HEART FAILURE WITH PRESERVED EJECTION FRACTION?
  108. SHOULD NORMAL CUTOFF VALUES FOR E/E’ AND BNP DIFFER IN THE PRESENCE OF OBESITY?
  109. DO PATIENTS WITH DIASTOLIC HEART FAILURE PROGRESS TO SYSTOLIC HEART FAILURE?
  110. Caveat medicus! Pulmonary hypertension in the elderly: a word of caution
  111. Does a Normal BNP Exclude Heart Failure with Preserved Ejection Fraction?
  112. Contractility and Ventricular Systolic Stiffening in Hypertensive Heart Disease
  113. Age-Associated Increases in Pulmonary Artery Systolic Pressure in the General Population
  114. Stress hormone and circulating biomarker profile of apical ballooning syndrome (Takotsubo cardiomyopathy): insights into the clinical significance of B-type natriuretic peptide and troponin levels
  115. Differentiation of tricuspid regurgitation from constrictive pericarditis: novel criteria for diagnosis in the cardiac catheterisation laboratory
  116. Invasive Hemodynamic Assessment in Heart Failure
  117. Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction
  118. Treatment of heart failure with preserved ejection fraction
  119. Severe heart failure in the setting of relatively mild mitral stenosis: The role of invasive hemodynamic assessment
  120. Abnormal Contractile Reserve Limits Exercise Capacity in Heart Failure with Preserved EF
  121. Impact of Aging on Pulmonary Hemodynamics in the General Population
  122. Depressed Myocardial Contractility Despite Normal Chamber Systolic Function in Heart Failure with Preserved Ejection Fraction
  123. Prevalence and Prognostic Significance of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction: A Population-Based Study
  124. Lung Diffusion and Alveolar-Capillary Recruitment during Exercise in Heart Failure with Preserved Ejection Fraction
  125. Ventricular–Vascular Interaction in Heart Failure
  126. Ventricular-Arterial Interaction in Patients with Heart Failure and a Preserved Ejection Fraction
  127. Contributors
  128. Response to Letter Regarding Article, “Cardiac Structure and Ventricular–Vascular Function in Persons With Heart Failure and Preserved Ejection Fraction From Olmsted County, Minnesota”
  129. Impact of Arterial Load and Loading Sequence on Left Ventricular Tissue Velocities in Humans
  130. Beyond Low-Density Lipoprotein Cholesterol
  131. Estimation of central pressure augmentation using automated radial artery tonometry
  132. Cardiac Structure and Ventricular–Vascular Function in Persons With Heart Failure and Preserved Ejection Fraction From Olmsted County, Minnesota
  133. Cardiovascular Features of Heart Failure With Preserved Ejection Fraction Versus Nonfailing Hypertensive Left Ventricular Hypertrophy in the Urban Baltimore Community
  134. Impaired Chronotropic and Vasodilator Reserves Limit Exercise Capacity in Patients With Heart Failure and a Preserved Ejection Fraction
  135. Mechanisms of Diastolic Dysfunction in Heart Failure
  136. Tricuspid Annular Displacement Predicts Survival in Pulmonary Hypertension
  137. Sildenafil Inhibits β-Adrenergic–Stimulated Cardiac Contractility in Humans